Abstract 5074: Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP

Authors: Ahmetmursel Ulusan, Praveen Rajendran, Wan-Mohaiza Dashwood, Altaf Mohammed, Shizuko Sei, Powel H. Brown, Eduardo Vilar-Sanchez, Roderick H. Dashwood

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-5074

Source: Full article